Table 3.
Therapeutic Antibody Profiling of ScFv Candidates.
| TAP Metrics | scFv32 | scFv43M2 | scFv51 |
|---|---|---|---|
| CDR length | 47 | 44 | 45 |
| CDR vicinity PSH score | 133.6982 | 119.791 | 134.2631 |
| CDR vicinity PPC score | 0.4761 | 3.1258 | 0.4023 |
| CDR vicinity PNC score | 0.0 | 0.0 | 0.0 |
| sFvCSP score | 2.1 | 12.4 | 2.31 |
Comparison among the anti-16E7 scFvs using the TAP computational tool by Raybould et al. [27] for evaluation of possible therapeutic development. Green boxes indicate a good agreement of the scores with those of post-phase I clinical-stage antibody therapeutics (CSTs); the amber box indicates a score that is less represented in the metric distribution of the 242 antibody therapeutics, considered for setting the parameters. PSH = Patches of Surface Hydrophobicity Metric; PPC = Patches of Positive Charge Metric; PNC = Patches of Negative Charge Metric; SFvCSP = Structural Fv Charge Symmetry Parameter. Results are available at the following links: http://opig.stats.ox.ac.uk/webapps/newsabdab/sabpred/tap_results/20200502_0570079 for scFv32; http://opig.stats.ox.ac.uk/webapps/newsabdab/sabpred/tap_results/20200502_0199339 for scFv43M2; http://opig.stats.ox.ac.uk/webapps/newsabdab/sabpred/tap_results/20200502_0278604 for scFv51 (accessed on 1 June 2020).